HIV i-Base is a treatment activist group, HIV-positive led and committed to providing timely HIV treatment information both to positive people and to health care professionals.
This includes technical publications like HIV Treatment Bulletin (HTB) and ARV4IDUs (Antiretrovirals for Injecting Drug Users) and non-techical treatment guides on starting and changing treatment, side effects, hepatitis C coinfection and HIV and pregnancy.
i-Base is involved in several community networks, including the UK Community Advisory Board (UK-CAB), the European AIDS Treatment Group (EATG), the European Community Advisory Board (ECAB) and the International Treatment Preparedness Coalition (ITPC) and the AIDS Treatment Activists Coalition (ATAC).
We have also developed close working relationships with NGOs in many different countries in Western and Eastern Europe and Africa. Copyright free i-Base material has been produced in over 40 languages.
We are directly involved in research with INSIGHT network, PENTA network, MRC studies in the UK, Metabolic Oversight Committee and D:A:D studies.
Treatment guides and i-Base authored articles in HTB may be reproduced by NHS, community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original source on the i-Base Web site is always appreciated. All i-Base material remains the copyright of HIV i-Base.
HIV i-Base receives unconditional educational grants from charitable trusts, individual donors and pharmaceutical companies. All editorial policies are strictly independent of funding sources.
HIV i-Base is a registered charity no.1081905 and company limited by guarantee no. 3962064.
How to Reach HIV i-Base
57a Great Suffolk Street
Latest by HIV i-Base
We Learn, We Think, We Change: Martin Fisher Foundation and Stiggy Launch Campaign to End HIV Stigma
The UK's Martin Fisher Foundation has produced a new set of videos about making HIV stigma history starring Stiggy, "the HIV stigmasaur."
More information about why an undetectable viral load stops HIV transmission (U=U).
A new 32-page resource from HIV i-Base explains HIV treatment by using a few easy pictures.
NHS England Fudges PrEP Access and Delays On-Demand Access to PrEP by Years; Blocks Doctors From Prescribing PrEP Now
"After almost a year of turmoil a new [NHS] press statement still fails to allow a single doctor to protect the health of their patients by prescribing PrEP," Simon Collins writes.
Do all drugs have side effects?
Even when drugs are very effective at treating a health problem, they sometimes affect other parts of your body.
This other activity is called a side effect or "adverse event" -- or referred to as drug toxicity.
Some symptoms in the first few weeks of treatment may be caused by immune stimulation or your body getting better. So what you think might be side effects might not be related to the drugs at all.
If your initial symptoms are only mild or moderate, ...
Associated drugs: abacavir* (Ziagen), Trizivir (abacavir+AZT+3TC ), Kivexa (abacavir+3TC), Triumeq (abacavir+3TC+dolutegravir) and cotrimoxazole (Septrin). HSR with other HIV drugs is rare.*
The main side effect associated with abacavir is a hyperse...
Bilirubin is an orange waste product; Hyper = increased; aemia = "in blood"
Associated drugs: atazanavir* (Reyataz); Evotaz (atazanavir+cobicistat); indinavir (Crixivan, no longer used).*
An increase in bilirubin (called hyperbilirubinaemia) is a c...
Associated drugs: T-20* (enfuvirtide, Fuzeon)*
This information is available in a T-20 factsheet (PDF file)
T-20 was approved in 2003 in Europe and was the first entry inhibitor. T-20 is now extremely rarely used because newer drugs are more effect...
Cholesterol and triglycerides are two types of fats (lipids) that are carried (and can be measured) in blood.
These fats perform essential functions, including making effective cell structures and processing vitamins A, D, E and K.
Cholesterol and ...